Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#2601 most reported symptom for this vaccine
Administration site induration has been reported 3 times in association with Zoster Live (Zostavax) vaccination in VAERS. This represents 0.0% of all 140,312 reports for this vaccine.
Among these reports, 0 mentioned death (0.00%) and 0 involved hospitalization (0.0%).
Administration site induration is the #2601 most frequently reported symptom for Zoster Live (Zostavax) out of 2827 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 3 reports of Administration site induration after Zoster Live (Zostavax) vaccination may seem alarming, but context is critical. With 140,312 total reports for this vaccine (representing many millions of doses), Administration site induration appears in only 0.0% of reports.
The mortality rate among these reports is very low at 0.00%, suggesting most cases are non-fatal.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.